同步放化疗与序贯放化疗治疗中晚期食管癌的临床研究  被引量:12

Clinical Research of Concurrent Chemoradiotherapy and Sequential Chemoradiotherapy of Advanced Esophageal Carcinoma

在线阅读下载全文

作  者:沈康[1] 肖庆成[1] 

机构地区:[1]南京医科大学第二附属医院泗阳分院肿瘤科,江苏宿迁223700

出  处:《肿瘤基础与临床》2011年第6期512-514,共3页journal of basic and clinical oncology

摘  要:目的比较同步放化疗与序贯放化疗治疗中晚期食管癌的近期疗效和长期生存率。方法 168例中晚期食管癌患者随机分为两组:同步放化疗组91例;序贯放化疗组77例。同步放化疗组:放疗2 Gy/次,总量50~56 Gy。同步化疗2周期,放疗结束后继续化疗4周期;序贯放化疗组:放疗2 Gy/次,总量60~64 Gy。待放疗结束后化疗6周期。两组化疗方案相同:顺铂20 mg/m2静脉滴注d1~5,替加氟400 mg/m2静滴d1~5。结果同步放化疗组有效率67.0%,序贯放化疗组有效率为59.7%,比较差异无统计学意义(P>0.05)。同步放化疗组1、3年生存率分别为73.6%、49.5%,序贯放化疗组1、3年生存率分别为45.5%、24.7%,比较差异均有统计学意义(P<0.05)。两组毒副反应发生率相似,均可耐受。结论同步放化疗治疗中晚期食管癌近期疗效肯定,长期生存有优势,毒副反应可以耐受。Objective To study the short term effect and long term survival rate of concurrent chemoradiotherapy and sequential chemoradiotherapy of advanced esophageal carcinoma. Methods All the 168 patients with advanced esophageal carcinoma were randomly divided into two groups. The 91 cases in the concurrent ehemoradiotherapy group: radiotherapy 2 Gy/time, the volume dose was 50-56 Gy; 2 cycles ot chemotherapy were given at the same time, 4 cycles of chemotherapy were given after the radiotherapy. The 77 cases in the sequential chemn- radiotherapy group : radiotherapy 2 Gy/time, the volume dose was 60-64 Gy ; 6 cycles of chemotherapy were given after the radiotherapy. The chemotherapy regimens of the two groups were the same : DDP 20 mg/m2 , intervenous drop infusion, d1-5 ; tegafur 400 mg/m2 , intervenous drop infusion, dl.5. Results The effective rate of the concurrent chemoradiotherapy group was 67.0%, and that of the sequential chemoradiotherapy group was 59.7% (P 〉 0.05). The 1-, 3-year survival rates of the concurrent chemoradiotherapy group were 73.6% and 49.5% , those of the sequential chemoradiotherapy group were 45.5% and 24.7% (P 〈 0.05 ). The toxicities of the two groups were indiscriminate, and could be tolerated. Conclusion The short term effect of concurrent chemoradiotherapy and sequential chemoradiotherapy are good for advanced esophageal carcinoma, and their toxicities can be tolerated; concurrent chemoradiotherapy has an advantage in the long term survival.

关 键 词:同步放化疗 序贯放化疗 中晚期食管癌 

分 类 号:R730.58[医药卫生—肿瘤] R735.1[医药卫生—临床医学]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象